Arctic Bioscience AS (OSL:ABS)

Market Cap	69.39M
Revenue (ttm)	44.40M
Net Income (ttm)	-47.93M
Shares Out	26.69M
EPS (ttm)	-1.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,442
Average Volume	81,370
Open	3.000
Previous Close	2.830
Day's Range	2.500 - 3.160
52-Week Range	1.650 - 16.800
Beta	1.39
RSI	31.30
Earnings Date	May 7, 2025

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand worldwide. The company was incorporated in 2011 and is headquartered in Ørsta, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 355
• Stock Exchange: Oslo Børs
• Ticker Symbol: ABS

Financial Performance

In 2024, Arctic Bioscience AS's revenue was 44.40 million, an increase of 31.55% compared to the previous year's 33.76 million. Losses were -47.93 million, 5.31% more than in 2023.